hpw - topbar hpw - topbar - diag hpw - topbar xce
 

Late Summer 2018 

Subscribe

Forward to a Friend

Share   

    

View Archived Issues

 
IN THIS ISSUE
 
 

We examine the world’s second largest pharmaceuticals market as Japan shifts from a traditional reimbursement assessment to a novel cost-effectiveness submission requirement. We look at new therapies for tardive dyskinesia. And we review Taiwan’s Center for Drug Evaluation on its 10-year anniversary.

 
 
 

 

 

 
HTA DECISION MAP
 

When HTA Decisions Occur, We Keep You Informed

 
 

Xcenda’s HTA Decision Map makes it easy to stay informed. Find out how new products are faring with HTA authorities in:

  • Australia
  • Canada
  • France
  • Germany
  • United Kingdom

 

 

 
HEARD ON THE STREET
 

“Today I can provide noble Lords with the strongest possible reassurance on the UK’s commitment to implement the (Clinical Trial Regulation) CTR. If the CTR comes into force during the implementation period, as it is currently expected to do in March 2020, it will apply to the UK. If this opportunity does not come to pass, the Government will seek to bring into UK law all relevant parts of the EU regulation that are within the UK’s control.”

 

— Baroness Goldie, affirming the UK’s commitment to align as closely as possible with EU rules on clinical trials following Brexit

 

 

 

 
HTA BY THE NUMBERS
 

26%

 

The average sales growth rate of 36 drugs with negotiated access on China’s National Reimbursement Drug List. Manufacturers of these higher-cost, mostly oncology therapies have agreed to lower pricing with the aim to increase total sales revenue through greater volume. While the average product achieved 26% revenue growth, the impact on individual products ranged widely from a 5% decline to 400% growth.

Source: China Expedites Price Reduction of Anticancer Drugs, PharmExec.com

     
 
GLOBAL REACH. LOCAL EXPERTISE.
 

Gain Global Market Access Insights. Let Our Experts Help.

 
 

Need insights for new geographic markets? Have pressing market access questions that could use the insight of local experts? Then partner with Xcenda and our Global Market Access Network (GMAN) advisors while you’re at ISPOR Europe 2018 in Barcelona, Spain. Gain local insights on pricing, reimbursement, and access from this team of global experts.

 

 

 

For more than 2 decades, companies have turned to Xcenda’s leading team of value experts, transforming evidence and market intelligence into effective global market access strategies and solutions. Founded in the application of health outcomes and reimbursement, it’s our goal to help prove the inherent worth of client products and services, maximize patient access, and enhance overall brand performance.

Explore our solutions >

 

 
 

Subscribe to the newsletter written specifically by and for Global HEOR and Market Access professionals.

 
 
 
EDITORS AND CONTRIBUTING AUTHORS
 

EDITOR-IN-CHIEF:
Kellie Meyer, PharmD, MPH
Vice President,
Global Health Economics &
Outcomes Research, Xcenda

MANAGING EDITOR:
Trent McLaughlin, BSc(Pharm), PhD
Vice President,
Real-World Evidence, Xcenda

 

EDITORIAL BOARD:

Josep Darba, PhD
Professor | Department of Economics | University of Barcelona

George Papadopoulos, BSc(Hons), GradDipEpi
President | Emerald Corporate Group

Ken Redekop, BSc, MPH, PhD
Visiting Associate Professor | National University of Singapore

Eldon Spackman, BA, MA, PhD
Co-Director | Institute for Public Health | University of Calgary

Keith Tolley
Director | Tolley Health Economics

Thomas Mittendorf, MSc, PhD
Vice President | Xcenda GmbH

Trent McLaughlin, BSc(Pharm), PhD
Vice President, Real-World Evidence | Xcenda

Michael Eaddy, PharmD, PhD
Vice President, Scientific Consulting | Xcenda

Jay Jackson, PharmD, MPH
Senior Vice President, Consulting Services | Xcenda

CONTRIBUTING AUTHORS:

David Campbell, PharmD, MS | Ryan Clark, PharmD, MBA, MS | Rhea Jang | Anuja Kanaskar, PharmD | Kristen Migliaccio-Walle | Kim Riggs, MPH

PRODUCTION:

Ellen Olson | Laurie Kozbelt | Elana Gruen

 

 

Late Summer 2018

Subscribe

Forward to a Friend

Share   

    

View Archived Issues

 
 

Connect with AmerisourceBergen:   AmerisourceBergen.com   I   LinkedIn   I   Twitter   I   AmerisourceBergen Insights

Connect with Xcenda:   Xcenda.com   I   LinkedIn   I  Twitter

This email was sent on behalf of Xcenda by HealthEconomics.Com, 449 S. Mill View Way, Ponte Vedra Beach, FL 32082.
If you don't wish to receive further Industry Leaders News Updates from us, you may immediately unsubscribe from this list here , or send your request in writing to the address above. Read more about our privacy policy here. You may also request a copy in writing using the address above.